Trial Profile
MulticEnter Trial of Rivaroxaban for Early disCharge of pUlmonaRY Embolism From the Emergency Department
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Pulmonary embolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms MERCURY PE
- Sponsors Janssen
- 28 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 22 Mar 2017.
- 28 Apr 2017 Status changed from active, no longer recruiting to completed.
- 20 Jan 2017 Status changed from recruiting to active, no longer recruiting.